<DOC>
	<DOCNO>NCT01925820</DOCNO>
	<brief_summary>Currently , several antiviral treatment effective suppression viral replication still fail cure HBV infection patient chronic hepatitis B ( CHB ) . Seven drug worldwide approve treatment CHB present : conventional IFN ( IFN ) alfa , lamivudine ( LAM ) , adefovir dipivoxil ( ADV ) , pegylated IFN ( Peg-IFN ) alfa , entecavir ( ETV ) , telbivudine ( LdT ) tenofovir ( TDF ) . Conventional Peg-IFN alfa monotherapy narrow range efficacy , associate several adverse effect inconvenient frequent injection . Oral nucleot ( ) ide analogue ( NA ) well tolerate ; virologic response NA frequently durable prolonged treatment associate emergence drug-resistant HBV mutant . Although best treatment choice CHB clarify yet , certain therapeutic concept could derive experience treat patient chronic hepatitis C human immunodeficiency virus ( HIV ) infection . A major advancement treat hepatitis C HIV infection development combination therapy . Combination therapy ever investigate patient CHB , optimal strategy remain identify . Entecavir , carbocyclic deoxyguanosine NA , one potent anti-HBV agent ever discover . In addition , 6-year drug resistance rate 1.2 % select lamivudine-naïve cohort . Pegylated interferon alfa-2a posse antiviral immunomodulatory effect . Overall , satisfactory virologic serologic response could achieve use pegylated IFN alfa around 30-44 % patient . Whether combination therapy use Peg-IFN alfa-2a plus ETV achieve long-term beneficial effect ETV Peg-IFN alfa-2a alone clarify . A prior single-arm pilot study suggest similar combination therapy may beneficial patient CHB . In proposal , investigator thus hypothesize efficacy use combination therapy Peg-IFN alfa-2a plus prolonged ETV superior use ETV Peg-IFN alfa-2a alone Peg-IFN may restore host immunity HBV prolong ETV maximize viral suppression . The objective clinical trial evaluate efficacy combination Peg-IFN alfa-2a dose 180 mcg administer subcutaneously per week ETV 0.5 mg daily 48 week follow ETV 0.5 mg daily monotherapy additional 96 week versus ETV 0.5 mg daily monotherapy 144 week Peg-IFN alfa-2a 180 mcg per week 48 week patient HBeAg-negative CHB . It open-label , randomize , comparative , multi-center clinical trial . The recruited patient equally randomize three treatment group . Treatment-free follow-up period 48 week group patient . The primary parameter `` Simultaneous achievement HBsAg titer 100 IU/ml HBV DNA 300 IU/ml 144 week start treatment '' , intention-to-treat analysis . Genotypic virologic resistance ETV also assess baseline end year 1 , 2 3 . The investigator anticipate rate HBsAg &lt; 100 IU/mL plus HBV DNA &lt; 300 IU/mL 3 year study period 30 % patient receive Peg-IFN therapy increase 45 % patient receive Peg-IFN plus entecavir therapy . With 5 % nominal significance level ( two-sided ) , 163 patient per group 1:1:1 ratio provide 80 % power detect difference 15 % treatment response rate group I III . Because 4-year study patient , investigator thus anticipate dropout rate may high 10 % . Accordingly , total 540 ( 180x3 ) patient recruit , order account dropout rate to10 % .</brief_summary>
	<brief_title>Pegasys Plus Entecavir Versus Entecavir Versus Pegasys Hepatitis B e Antigen-Negative Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Adult male female , 20 70 year age Patient must document positive serum HBsAg minimum 6 month prior entry study . Patients must show evidence HBV replication hepatitis document Positive serum HBV DNA within 3 month prior entry ( HBV DNA &gt; 10,000 copies/mL 2000 IU/mL ) . Negative serum HBeAg within 3 month prior entry . Documented presence abnormal alanine aminotransferase ( ALT ) twice within 6 month prior entry , least 3 month apart ( 2 10 fold upper normal level ) . Naïve interferon , lamivudine , telbivudine ; patient ever receive adefovir , tenofovir entecavir could enrol , discontinue 3 month . 2 . Compensated liver disease follow minimum hematological serum biochemical criterion : Hemoglobin value 12 gm/dL gender WBC 3,000/mm3 Neutrophil count 1,500/ mm3 Platelets 100,000/ mm3 PT prolong 3 sec , INR 1.2 Total bilirubin 2 mg/dL Albumin &gt; 3.5 g/dL Uric acid within normal range Serum creatinine 123.76 mmol/L ( 1.4 mg/dL ) Hemoglobin A1C 8.5 % diabetic patient ( whether medication and/or control diet ) 3 . Thyroid stimulate hormone ( TSH ) , within normal range ( subject require medication maintain TSH level normal range eligible other.inclusion/exclusion criterion meet ) 4 . Negative serum antibody hepatitis C ( antiHCV ) hepatitis D ( antiHDV ) 5 . Negative antibody human immunodeficiency virus ( antiHIV ) 6 . Alfafetoprotein within normal range ( obtain within previous year , elevate &lt; 100 ng/ml , negative ultrasound hepatocellular carcinoma within prior 3 month require . ) 7 . Subject must willing give write informed consent able adhere dose visit schedule *Patients well compensate liver cirrhosis ( ChildPugh A ) , absence splenomegaly ( abdominal ultrasonography ) varix ( patient ever receive upper GI endoscope ) , could enrol . 1 . Women pregnant nursing . 2 . Prior treatment hepatitis interferon , lamivudine , telbivudine , investigational agent . 3 . Prior treatment hepatitis immunomodulatory drug within previous 2 year . 4 . Suspected hypersensitivity interferon . 5 . Have evidence cirrhosis presence splenomegaly varix , evidence decompensated cirrhosis . 6 . History severe psychiatric disease , especially depression . 7 . Concurrent malignancy ( include hepatocellular carcinoma ) . 8 . Unstable significant cardiovascular disease ( e.g. , angina , congestive heart failure , recent myocardial infarction , severe hypertension significant arrhythmia ; subject ECG show clinically significant abnormality ) . 9 . Prolonged exposure know hepatotoxin alcohol drug 10 . History thyroid disease poorly control prescribed medication 11 . Poorly control diabetes mellitus 12 . Have suspect confirm significant hepatic disease etiology HBV ( e.g. , alcohol , autoimmune disease etc . ) 13 . Patients coinfected hepatitis C , hepatitis D /or HIV 14 . Severe renal disease myeloid dysfunction 15 . History organ transplantation cornea hair transplant 16 . Any medical condition requiring , likely require course study , chronic systemic administration steroid 17 . Any condition opinion investigator would make subject unsuitable enrollment , could interfere subject participate complete protocol .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Hepatitis B , Entecavir , Pegylated IFN</keyword>
</DOC>